Feb 2017 $3 M No. 10 $2 to $10 million 8
Hepalife Technologies Inc.: Raise no. 10, Feb 2017 × Investors in this round 8 investors had bought by the notice of Mar 13, 2017: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $196,180
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brad Barton · Executive Officer · Chief Operating Officer Brian Posner · Executive Officer · Chief Financial Officer, Treasurer and Secretary David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer Pellegrino Pionati · Executive Officer · Chief Strategy and Marketing Officer Gary Restani · Director · Director Jeffrey Sklar · Director · Director Jerome Zeldis · Director · Director Joseph Leone · Director · Director Mark Wagner · Director · Director Winston Kung · Director · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Cova Capital Partners, LLC (CRD 109761) · Syosset, New York Sold in CA, NJ, NY, PA Rodman & Renshaw, LLC (CRD 281264) · broker-dealer H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, NJ Remarks in the notice On fees: “$161,980 was paid to Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. $34,200 was paid to Cova Capital Partners, LLC.”Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 13, 2017. Read the notice at the SEC .
equity SEC May 2014 $2 M Issued in a merger or acquisition $2 to $10 million 43
Hepalife Technologies Inc.: Private sale, May 2014 × Investors in this round 43 investors had bought by the notice of May 15, 2014: 43 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $7 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Posner · Executive Officer · Chief Financial Officer, Treasurer and Secretary of the Issuer David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Pearsen · Director Perry Karsen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The former stockholders of Choice Therapeutics, Inc. may receive in aggregate up to an additional $5 million in shares of the Common Stock of Alliqua, Inc., in an earnout payment 37 months following the closing.”Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed May 15, 2014. Read the notice at the SEC .
equity SEC Apr 2014 $15 M No. 9 $10 to $50 million 18
Hepalife Technologies Inc.: Raise no. 9, Apr 2014 × Investors in this round 18 investors had bought by the notice of Apr 28, 2014: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $598,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Posner · Executive Officer · Chief Financial Officer, Treasurer and Secretary of the Issuer David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Pearsen · Director Perry Karsen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Summer Street Research Partners (CRD 127412) · New York, New York Sold in CT, MA, MD, NJ, NY, PA Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 28, 2014. Read the notice at the SEC .
equity, options SEC Nov 2013 $7 M No. 8 $2 to $10 million 12
Hepalife Technologies Inc.: Raise no. 8, Nov 2013 × Investors in this round 12 investors had bought by the notice of Nov 25, 2013: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $490,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Posner · Executive Officer · Chief Financial Officer of the Issuer David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Londoner · Director Kenneth Pearsen · Director Richard Rosenblum · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Summer Street Research Partners (CRD 127412) · New York, New York Sold in CA, MA, MD, NY, PA Remarks in the notice On fees: “The Issuer also issued a five year warrant to purchase 136,585 shares of common stock at an exercise price of $5.69 per share to the placement agent as consideration for serving as the placement agent.”Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 25, 2013. Read the notice at the SEC .
equity, options SEC Nov 2013 $6 M No. 7 $2 to $10 million 1
Hepalife Technologies Inc.: Raise no. 7, Nov 2013 × Investors in this round 1 investor had bought by the notice of Nov 25, 2013: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Posner · Executive Officer · Chief Financial Officer of the Issuer David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Londoner · Director Kenneth Pearsen · Director Richard Rosenblum · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 25, 2013. Read the notice at the SEC .
equity, options SEC Oct 2013 $1 M No. 6 Under $2 million 1
Hepalife Technologies Inc.: Raise no. 6, Oct 2013 × Investors in this round 1 investor had bought by the notice of Nov 18, 2013: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $70,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice Brian Posner · Executive Officer · Chief Financial Officer of the Issuer David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Londoner · Director Kenneth Pearsen · Director Richard Rosenblum · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Summer Street Research Partners (CRD 127412) · New York, New York Sold in MA Remarks in the notice On fees: “Issuer also issued five year warrants to purchase (i) 388,889 shares of common stock at a $.10 per share exercise price and (ii) 388,889 shares of common stock at an $.11 per share exercise price to the placement agent as consideration for its service.”Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 18, 2013. Read the notice at the SEC .
equity, options SEC Jun 2013 $2 M No. 5 Under $2 million 30
Hepalife Technologies Inc.: Raise no. 5, Jun 2013 × Investors in this round 30 investors had bought by the notice of Jul 9, 2013: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $62,632
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer Steven Berger · Executive Officer · Chief Financial Officer of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Londoner · Director Kenneth Pearsen · Director Richard Rosenblum · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Summer Street Research Partners (CRD 127412) · New York, New York Sold in CA, CO, CT, FL, NJ, NY, PA Remarks in the notice On fees: “The Issuer also issued a five year warrant to purchase 773,235 shares of common stock at an exercise price of $0.097 per share to the placement agent as consideration for serving as the placement agent.”Signed by Steven Berger, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 9, 2013. Read the notice at the SEC .
equity, options SEC Apr 2013 $1 M No. 4 Under $2 million 26
Hepalife Technologies Inc.: Raise no. 4, Apr 2013 × Investors in this round 26 investors had bought by the notice of Jun 10, 2013: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $99,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer Steven Berger · Executive Officer · Chief Financial Officer of the Issuer David Stefansky · Director Jeffrey Sklar · Director Jerome Zeldis · Director Joseph Leone · Director Kenneth Londoner · Director Kenneth Pearsen · Director Richard Rosenblum · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in AR, CA, FL, IA, IL, KY, NC, NJ, OH, OK, PA, TX Remarks in the notice On fees: “The Issuer also issued a five year warrant to purchase 1,222,222 shares of common stock at an exercise price of $0.097 per share to the placement agent as consideration for serving as the placement agent.”Signed by Steven Berger, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2013. Read the notice at the SEC .
equity, options SEC Feb 2012 $1 M No. 3 Under $2 million 12
Hepalife Technologies Inc.: Raise no. 3, Feb 2012 × Investors in this round 12 investors had bought by the notice of Mar 1, 2012: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $55,475
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Florida People named in the notice Richard Rosenblum · Executive Officer, Director · President and Director of the Issuer Steven C. Berger · Executive Officer · Chief Financial Officer of the Issuer David Stefansky · Director · Chairman of the Issuer Jeffrey M. Sklar · Director Joseph M. Leone · Director Joseph Sierchio · Director Kenneth M. Pearsen · Director Michael M. Goldberg · Director Nochum M. Stein · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Palladium Capital Advisors, LLC (CRD 129400) · New York, New York Sold in FL, NJ, NY, and outside the US Remarks in the notice On fees: “The Issuer also issued a five year warrant to purchase 1,109,500 shares of common stock at an exercise price of $0.069 per share to the placement agent as consideration for serving as the placement agent.”On the amounts: “The Issuer issued 21,000,000 shares of common stock and five year warrants to purchase an aggregate of 10,500,000 shares of common stock to the investor in exchange for aggregate consideration of $1,050,000.”Signed by Steven Berger, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 1, 2012. Read the notice at the SEC .
equity, options SEC Mar 2011 $1 M No. 2 Under $2 million 1
Hepalife Technologies Inc.: Raise no. 2, Mar 2011 × Investors in this round 1 investor had bought by the notice of Mar 17, 2011: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $154,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Florida People named in the notice David Stefansky · Executive Officer, Director · Chairman of the Issuer Richard Rosenblum · Executive Officer, Director · President and Director of the Issuer Steven C. Berger · Executive Officer · Chief Financial Officer of the Issuer Jeffrey M. Sklar · Director Joseph M. Leone · Director Joseph Sierchio · Director Kenneth M. Pearsen · Director Michael M. Goldberg · Director Nochum M. Stein · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Palladium Capital Advisors, LLC (CRD 129400) · New York, New York Sold in FL Remarks in the notice On fees: “The Issuer issued 437,500 shares of common stock and a five year warrant to purchase 312,500 shares of common stock to the placement agent as consideration for serving as the placement agent.”On the amounts: “The Issuer issued 6,250,000 shares of common stock and a five year warrant to purchase 6,250,000 shares of common stock to the investor in exchange for aggregate consideration of $1,000,000.”Signed by Richard Rosenblum, President and Director of the Issuer. Source: SEC Form D, newest notice filed Mar 17, 2011. Read the notice at the SEC .
equity, options SEC May 2010 $1 M No. 1 Under $2 million 15
Hepalife Technologies Inc.: Raise no. 1, May 2010 × Investors in this round 15 investors had bought by the notice of May 25, 2010: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $1 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $114,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Florida People named in the notice David Stefansky · Executive Officer, Director · Chairman and Director of the Issuer Richard Rosenblum · Executive Officer · President of the Issuer Steven C. Berger · Executive Officer · Chief Financial Officer, Treasurer and Secretary of the Issuer Joseph C. Sierchio · Director · Director of the Issuer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Palladium Capital Advisors, LLC (CRD 129400) · New York, New York Sold in FL, NY, TX Remarks in the notice On fees: “Palladium Capital Advisors, LLC received a cash fee of $114,000, plus Series E Warrants to purchase 456,000 shares of common stock, Series F Warrants to purchase 456,000 shares of common stock, and 2,000,000 shares of common stock.”Signed by Steven C. Berger, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 25, 2010. Read the notice at the SEC .
equity, options SEC